O2 Other
A 5-year single center experience in IABP treatment

List of Authors: Emmi Saura, Jarmo Gunn, Jukka Savola
Edition name or number: SATS & Svenska Thoraxmötet 2014
Place: Malmö, Sweden
Publication year: 2014
Number of pages: 1


Background: Intra-aortic balloon pump (IABP) treatment is used as an adjunct for hemodynamic compromise perioperatively in cardiac surgery and in hemodynamic shock of other etiology. Epidemiological data on long term survival of patients treated with IABP is scarce.

Methods: Population of 223 consecutive patients treated with IABP at a tertiary hospital’s ICU. 203 patients had underwent cardiac surgery and 20 patients were nonoperative. Data on perioperative treatment and baseline values as well as data on mortality up to 1 year was obtained from the hospital registry.

Results: Mean age was 66±10 years. 30 –day mortality was 23.2% overall, 37.8% for nonoperative patients and 22.1% for surgical patients. 1 –year mortality was 26.3% overall, 55% for nonperative patients and 24.5% for surgical patients. 1 –year mortality was lowest for isolated CABG patients (15.3%). There were 14 (6.3%) complications requiring operative treatment (ischaemia, bleeding or infection). 1 –year survival for 30 –day survivors was 96.9 %. Predictors of 30 –day mortality on Cox regression were critical preoperative state, non-CABG surgery and nonoperative treatment. Predictors of 1 –year mortality were the same and a history of cardiac surgery. Timing of IABP insertion (preoperative, intraoperative, postoperative) in surgical patients did not predict mortality and mortality was similar for all timing groups.

Conclusions: IABP treatment is safe with few serious complications. Timing of IABP placement is not related to survival. Survival at 1 year follow-up is excellent after an initially high mortality for cardiac surgical patients treated for hemodynamic compromise with aortic counterpulsation. 


Internal Authors/Editors

Last updated on 2019-21-08 at 23:09